Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combined Chemotherapy and PD-1 Antibody(SHR-1210) With or Without Low-dose Decitabine Priming for Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL):Two Stage, Phase I/II Trail

Trial Profile

Combined Chemotherapy and PD-1 Antibody(SHR-1210) With or Without Low-dose Decitabine Priming for Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL):Two Stage, Phase I/II Trail

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2018

At a glance

  • Drugs Camrelizumab (Primary) ; Decitabine (Primary) ; Doxorubicin; Gemcitabine; Vinorelbine
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Nov 2018 Treatment arms has been changed fro 2 to 1 and study design has been changed from Parallel Assignment to Single Group Assignment.
    • 29 Nov 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
    • 29 Nov 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top